|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2006-1-31
|
|
pubmed:abstractText |
This was a multinational, open-label, randomized phase III trial comparing yttrium-90-labeled murine HMFG1 (90Y-muHMFG1) plus standard treatment versus standard treatment alone in patients with epithelial ovarian cancer (EOC) who had attained a complete clinical remission after cytoreductive surgery and platinum-based chemotherapy.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
pubmed-author:BenignoBenedict BBB,
pubmed-author:EpenetosAgamemnon AAA,
pubmed-author:FalkeTheoT,
pubmed-author:JoblingTomT,
pubmed-author:LambertJoannaJ,
pubmed-author:LopesAlbertoA,
pubmed-author:MarkowskaJanicaJ,
pubmed-author:MassugerLeon FLF,
pubmed-author:SeidenMichael VMV,
pubmed-author:SoperJohn TJT,
pubmed-author:SpiegelGregoryG,
pubmed-author:StampGordonG,
pubmed-author:ThurstonDennisD,
pubmed-author:VerheijenRené HRH,
pubmed-author:VyzulaRostislavR
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
24
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
571-8
|
|
pubmed:dateRevised |
2011-8-1
|
|
pubmed:meshHeading |
pubmed-meshheading:16446329-Adult,
pubmed-meshheading:16446329-Aged,
pubmed-meshheading:16446329-Antibodies, Monoclonal,
pubmed-meshheading:16446329-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16446329-Carcinoma,
pubmed-meshheading:16446329-Chemotherapy, Adjuvant,
pubmed-meshheading:16446329-Disease-Free Survival,
pubmed-meshheading:16446329-Female,
pubmed-meshheading:16446329-Humans,
pubmed-meshheading:16446329-Infusions, Parenteral,
pubmed-meshheading:16446329-Laparoscopy,
pubmed-meshheading:16446329-Middle Aged,
pubmed-meshheading:16446329-Ovarian Neoplasms,
pubmed-meshheading:16446329-Proportional Hazards Models,
pubmed-meshheading:16446329-Remission Induction,
pubmed-meshheading:16446329-Second-Look Surgery,
pubmed-meshheading:16446329-Treatment Failure,
pubmed-meshheading:16446329-Yttrium Radioisotopes
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission.
|
|
pubmed:affiliation |
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, VU University Medical Center, Amsterdam, The Netherlands. r.verheijen@vumc.nl
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase III
|
